Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013681
Chunk: 8

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 8
---
 number of hyperglycemic
events.

MTX110

MTX110 is a solubilised
formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via
convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the brain tumor, by-passing the blood-brain barrier
and potentially avoiding systemic toxicity. All three types of brain cancer being studied are orphan.

Recurrent Glioblastoma (“rGBM”)

Our Phase
1 MAGIC-G1 study (NCT05324501) of MTX110 in rGBM has completed the dose escalation part of the study with the recruitment of the fourth
patient in Cohort A. Overall survival was reported as between 11 and 12 months. Glioblastoma virtually always recurs with median Progression
Free Survival of 1.5–6.0 months and median Overall Survival of 2.0–9.0 months.

Diffuse Midline Glioma (“DMG”)

In February
2024 we announced headline data from a Phase 1 IIT study conducted by Columbia University in newly diagnosed patients with DMG. As this
was the first ever study of repeated infusions to the pons via an implanted CED catheter, the primary objective of the study was safety
and tolerability and, accordingly, the number of infusions was limited to two, each of 48 hours, seven days apart in nine patients. One
patient suffered a severe adverse event assessed by the investigators as not related to the study drug. Although not powered to reliably
demonstrate efficacy, median Overall Survival of patients in the study was 16.5 months compared with median survival rate in a cohort
of 316 cases of 10.0 months.

Study
investigators subsequently presented the results of the trial at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024)
in Philadelphia, PA.

Medulloblastoma

An IIT
Phase I study of MTX110 in medulloblastoma remains ongoing at the University of Texas.

Due to resource
constraints, MTX110 has been de-prioritised and there are no current development activities being undertaken.

| 6 |

Financing

Equity Line of Credit

In January 2025,
we entered into a securities purchase agreement, or equity line of credit (“ELOC”),